Rocket Lab's Space Force Victory Gets Buried Under a $9 Billion IPO Shadow

Rocket Lab stock slides 22% on SpaceX IPO capital rotation; Q1 revenue up 63%, backlog at record $2.2B, Neutron rocket remains key catalyst.

The most punishing week for Rocket Lab shareholders in over a year has less to do with rockets exploding and more to do with a single word: SpaceX. The stock shed 22.36 percent in five days, sliding from a 52-week high of €133.80 at the end of May to €95.50 by Friday's close. Yet behind the rout lies a story of rotating capital, not crumbling operations.

The catalyst is the long-awaited initial public offering of Elon Musk's SpaceX, expected around mid-June. Institutional investors are liquidating positions in publicly traded space stocks to free up cash for what could be the largest IPO in the sector's history. Rocket Lab, which had surged more than 300 percent over the past twelve months and served as the liquid proxy for space exposure, has borne the brunt of that repositioning. The result: a near-29 percent peak-to-trough dive in under two weeks.

Insider activity has added to the unease. Over the past 90 days, company insiders disposed of shares worth roughly $66.9 million. Director Alexander R. Slusky and Senior Vice President Arjun Kampani executed significant sales in late May and early June — uncomfortably close to the stock's high. While such transactions do not necessarily signal a loss of faith, they have amplified skepticism during a period already defined by heavy selling pressure.

A separate development — an explosion at a Blue Origin test stand in late May — initially rattled the broader space sector. The impact, however, was quickly eclipsed by stronger-than-expected U.S. jobs data showing 172,000 new positions, more than double forecasts. That reignited interest-rate fears, which punish high-growth technology names disproportionately. And SpaceX itself added to the headwinds by trimming its IPO valuation target from an earlier $2 trillion to roughly $1.77 trillion, triggering a sector-wide re-rating.

All of this has obscured what is, by most operational measures, a thriving business. Rocket Lab reported first-quarter 2026 revenue of $200.35 million, a 63.4 percent year-over-year jump. Its backlog stands at a record $2.2 billion, underpinned by 70 contracted launches. The company is also transforming itself from a pure launch provider into a full-spectrum space systems integrator. In May, it acquired Motiv Space Systems, a California robotics specialist with NASA Mars mission pedigree, and secured a $90 million contract with the U.S. Space Force under the Heimdall program to build satellites for geostationary orbit surveillance.

On the launch pad, attention now turns to the upcoming HASTE mission "Curveball" from Wallops Island, Virginia. Successful flights have historically provided short-term stabilization for the stock. Longer-term, the Neutron rocket — designed to lift 13,000 kilograms to orbit and still targeting a first flight in 2026 — remains the company's most ambitious growth driver.

Technically, the stock's relative strength index at 46.2 sits in neutral territory, neither oversold nor overbought. At €95.50, Rocket Lab still trades about 15 percent above its 50-day moving average of €83.61 and a commanding 55 percent above its 200-day average of €61.64. The upward structure, in other words, remains intact — for now. The annualized volatility of 132.57 percent is a reminder that this is a stock that can reverse course violently in either direction.

The coming weeks will test whether the SpaceX IPO rotation is a temporary blip or the beginning of a more lasting repositioning. If the market greets the SpaceX listing with enthusiasm, the capital rotation could ease and Rocket Lab may recover. If not, the pressure could persist. Either way, the company's backlog and expanding defense footprint give it a foundation that few of its publicly listed peers can match.